128 related articles for article (PubMed ID: 17510207)
1. Phase I trial of weekly paclitaxel and BMS-214662 in patients with advanced solid tumors.
Bailey HH; Alberti DB; Thomas JP; Mulkerin DL; Binger KA; Gottardis MM; Martell RE; Wilding G
Clin Cancer Res; 2007 Jun; 13(12):3623-9. PubMed ID: 17510207
[TBL] [Abstract][Full Text] [Related]
2. A phase I trial of the novel farnesyl protein transferase inhibitor, BMS-214662, in combination with paclitaxel and carboplatin in patients with advanced cancer.
Dy GK; Bruzek LM; Croghan GA; Mandrekar S; Erlichman C; Peethambaram P; Pitot HC; Hanson LJ; Reid JM; Furth A; Cheng S; Martell RE; Kaufmann SH; Adjei AA
Clin Cancer Res; 2005 Mar; 11(5):1877-83. PubMed ID: 15756013
[TBL] [Abstract][Full Text] [Related]
3. Phase I clinical trial of the farnesyltransferase inhibitor BMS-214662 administered as a weekly 24 h continuous intravenous infusion in patients with advanced solid tumors.
Eder JP; Ryan DP; Appleman L; Zhu AX; Puchalski T; He X; Sonnichsen DS; Cooper M; Wright J; Clark JW; Supko JG
Cancer Chemother Pharmacol; 2006 Jul; 58(1):107-16. PubMed ID: 16362299
[TBL] [Abstract][Full Text] [Related]
4. A phase I pharmacokinetic and pharmacodynamic study of the farnesyl transferase inhibitor BMS-214662 in combination with cisplatin in patients with advanced solid tumors.
Mackay HJ; Hoekstra R; Eskens FA; Loos WJ; Crawford D; Voi M; Van Vreckem A; Evans TR; Verweij J
Clin Cancer Res; 2004 Apr; 10(8):2636-44. PubMed ID: 15102665
[TBL] [Abstract][Full Text] [Related]
5. Phase I and pharmacokinetic study of the new taxane analog BMS-184476 given weekly in patients with advanced malignancies.
Plummer R; Ghielmini M; Calvert P; Voi M; Renard J; Gallant G; Gupta E; Calvert H; Sessa C
Clin Cancer Res; 2002 Sep; 8(9):2788-97. PubMed ID: 12231518
[TBL] [Abstract][Full Text] [Related]
6. A phase I trial to determine the safety, pharmacokinetics, and pharmacodynamics of intercalated BMS-690514 with paclitaxel/carboplatin (PC) in advanced or metastatic solid malignancies.
Chow LQ; Jonker DI; Dy GK; Nicholas G; Fortin C; Patricia D; Adjei AA; Belani CP; Gupta A; Park JS; Zhang S; Sbar EI; Laurie SA
Cancer Chemother Pharmacol; 2013 May; 71(5):1273-85. PubMed ID: 23468081
[TBL] [Abstract][Full Text] [Related]
7. Phase I and pharmacokinetic study of BMS-188797, a new taxane analog, administered on a weekly schedule in patients with advanced malignancies.
Advani R; Fisher GA; Lum BL; Jambalos C; Cho CD; Cohen M; Gollerkeri A; Sikic BI
Clin Cancer Res; 2003 Nov; 9(14):5187-94. PubMed ID: 14613998
[TBL] [Abstract][Full Text] [Related]
8. Phase I evaluation of continuous 5-fluorouracil infusion followed by weekly paclitaxel in patients with advanced or recurrent gastric cancer.
Kondo K; Kobayashi M; Kojima H; Hirabayashi N; Kataoka M; Araki K; Matsui T; Takiyama W; Miyashita Y; Nakazato H; Nakao A; Sakamoto J
Jpn J Clin Oncol; 2005 Jun; 35(6):332-7. PubMed ID: 15961435
[TBL] [Abstract][Full Text] [Related]
9. Phase I study of the farnesyltransferase inhibitor BMS-214662 given weekly in patients with solid tumors.
Papadimitrakopoulou V; Agelaki S; Tran HT; Kies M; Gagel R; Zinner R; Kim E; Ayers G; Wright J; Khuri F
Clin Cancer Res; 2005 Jun; 11(11):4151-9. PubMed ID: 15930351
[TBL] [Abstract][Full Text] [Related]
10. Phase I clinical trial of the farnesyltransferase inhibitor BMS-214662 given as a 1-hour intravenous infusion in patients with advanced solid tumors.
Ryan DP; Eder JP; Puchlaski T; Seiden MV; Lynch TJ; Fuchs CS; Amrein PC; Sonnichsen D; Supko JG; Clark JW
Clin Cancer Res; 2004 Apr; 10(7):2222-30. PubMed ID: 15073096
[TBL] [Abstract][Full Text] [Related]
11. Phase I study of BMS-214662, a farnesyl transferase inhibitor in patients with acute leukemias and high-risk myelodysplastic syndromes.
Cortes J; Faderl S; Estey E; Kurzrock R; Thomas D; Beran M; Garcia-Manero G; Ferrajoli A; Giles F; Koller C; O'Brien S; Wright J; Bai SA; Kantarjian H
J Clin Oncol; 2005 Apr; 23(12):2805-12. PubMed ID: 15728224
[TBL] [Abstract][Full Text] [Related]
12. Phase I study of paclitaxel (taxol) and pegylated liposomal doxorubicin (caelyx) administered every 2 weeks in patients with advanced solid tumors.
Mavroudis D; Kouroussis Ch; Kakolyris S; Agelaki S; Kalbakis K; Androulakis N; Souglakos J; Samonis G; Georgoulias V
Oncology; 2002; 62(3):216-22. PubMed ID: 12065868
[TBL] [Abstract][Full Text] [Related]
13. Phase I trial of weekly cisplatin, irinotecan and paclitaxel in patients with advanced gastrointestinal cancer.
Tew WP; Radovich D; O'Reilly E; Schwartz G; Schrag D; Saltz LB; Kelsen DP; Kepler S; Ilson DH
Invest New Drugs; 2009 Aug; 27(4):366-73. PubMed ID: 18956138
[TBL] [Abstract][Full Text] [Related]
14. Phase I dose-finding and pharmacokinetic study of paclitaxel and carboplatin with oral valspodar in patients with advanced solid tumors.
Patnaik A; Warner E; Michael M; Egorin MJ; Moore MJ; Siu LL; Fracasso PM; Rivkin S; Kerr I; Litchman M; Oza AM
J Clin Oncol; 2000 Nov; 18(21):3677-89. PubMed ID: 11054441
[TBL] [Abstract][Full Text] [Related]
15. Phase I study of weekly paclitaxel and liposomal doxorubicin in patients with advanced solid tumours.
Androulakis N; Kouroussis C; Mavroudis D; Kakolyris S; Souglakos J; Agelaki S; Kalbakis K; Malas K; Pallis A; Samonis G; Georgoulias V
Eur J Cancer; 2002 Oct; 38(15):1992-7. PubMed ID: 12376203
[TBL] [Abstract][Full Text] [Related]
16. Phase I trial of weekly irinotecan and paclitaxel combined with carboplatin in patients with advanced cancer: a Hellenic Cooperative Oncology Group Study.
Briasoulis E; Golfinopoulos V; Karina M; Papakostas P; Pavlidis N; Fountzilas G
Anticancer Drugs; 2010 Sep; 21(8):785-9. PubMed ID: 20647930
[TBL] [Abstract][Full Text] [Related]
17. Phase I and pharmacokinetic study of BMS-184476, a taxane with greater potency and solubility than paclitaxel.
Hidalgo M; Aylesworth C; Hammond LA; Britten CD; Weiss G; Stephenson J; Schwartz G; Patnaik A; Smith L; Molpus K; Felton S; Gupta E; Ferrante KJ; Tortora A; Sonnichsen DS; Skillings J; Rowinsky EK
J Clin Oncol; 2001 May; 19(9):2493-503. PubMed ID: 11331328
[TBL] [Abstract][Full Text] [Related]
18. A phase I and pharmacokinetic study of losoxantrone and paclitaxel in patients with advanced solid tumors.
Diab SG; Baker SD; Joshi A; Burris HA; Cobb PW; Villalona-Calero MA; Eckhardt SG; Weiss GR; Rodriguez GI; Drengler R; Kraynak M; Hammond L; Finizio M; Von Hoff DD; Rowinsky EK
Clin Cancer Res; 1999 Feb; 5(2):299-308. PubMed ID: 10037178
[TBL] [Abstract][Full Text] [Related]
19. Phase I study of docetaxel and topotecan in patients with solid tumors.
Tkaczuk KH; Zamboni WC; Tait NS; Meisenberg BR; Doyle LA; Edelman MJ; Hausner PF; Egorin MJ; Van Echo DA
Cancer Chemother Pharmacol; 2000; 46(6):442-8. PubMed ID: 11138457
[TBL] [Abstract][Full Text] [Related]
20. Phase IB and pharmacological study of the novel taxane BMS-184476 in combination with doxorubicin.
Sessa C; Perotti A; Salvatorelli E; Minotti G; Viganò L; Lladò A; Capri G; Locatelli A; Colombini S; Peccatori F; Voi M; Marsoni S; Gianni L
Eur J Cancer; 2004 Mar; 40(4):563-70. PubMed ID: 14962724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
